Halia Therapeutics to Showcase Innovative Pipeline at BIO Investment & Growth Summit Halia Therapeutics will present its strategy and clinical advancements at the BIO Investment & Growth Summit, focusing on novel therapies targeting inflammation.

Halia Therapeutics to Showcase Innovative Pipeline at BIO Investment & Growth Summit #USA #Halia_Therapeutics #Lehi #NEK7 #inflammasome_inhibitors

#Research

ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity doi.org/10.1186/s435...

#ML345 #NLRP3 #inflammasome #inhibitor #NEK7 #InflammatoryDisease #Miscarriage

ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity - Molecular Biomedicine Excessive activation of the NOD-like receptor pyrin domain–containing protein 3 (NLRP3) inflammasome plays a key role in the pathogenesis of various inflammatory diseases. Despite the development of s...

#Research
ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity doi.org/10.1186/s435...

#ML345 #NLRP3 #inflammasome #inhibitor #NEK7 #InflammatoryDisease #Miscarriage